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Abstract
Involvement of the adrenal gland in kidney cancer represents a unique site of metastasis with a distinct clinical course. The cases are typically 
resistant to immune therapy and need local therapy management. A case series of patients with adrenal metastases was reviewed to highlight the 
nuances of clinical course and therapy. We reviewed renal cancer carcinoma (RCC) cases with adrenal metastases at Karmanos Cancer Center, 
Detroit MI. Medical records were reviewed to collect relevant case information. Next-generation sequencing, tumor mutation burden testing, 
and programmed death ligand biomarkers were evaluated in five cases. Twelve cases were reviewed; all were males with a median age of 49.5 
years. Three patients presented with adrenal metastases only and were treated with local therapy. Three received interleukin-2 (IL-2). One patient 
relapsed with bilateral adrenal lesions after 11 years of remission, post-IL-2 therapy. Five cases received immune checkpoint inhibitor (ICI) and 
one received antivascular therapy. ICI therapy was followed by ablation of residual adrenal metastases in three patients. Genomic profiling was 
available in five cases. All were BAP1 and PD-L1 negative.Pathogenic mutations in PBRM1, SETD2, and VHL were noted. All patients with 
residual adrenal metastases responded to antivascular therapies or to local ablation. One patient died 17 years after diagnosis and 11 patients are 
alive at a median follow-up of 9.5 years. Adrenal metastases in RCC have a distinct clinical course. They can represent a sanctuary site of relapse/
residual disease following treatment with immune therapy. Management with local therapy can induce durable remissions. Systemic management with 
antivascular therapies also demonstrated favorable responses. Further investigation should focus on the unique clinical course and optimal manage-
ment of adrenal metastases in kidney cancer.
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Renal cell carcinoma (RCC) is a heterogenous disease. 
The spectrum of  clinical outcomes can range from overall 
survival of  few months to many years. The current risk 
profiling established by the International Metastatic Dis-
ease Consortium (IMDC) involves the use of  clinical fac-
tors such as time from nephrectomy, anemia, performance 
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SureSelect XT assay (Agilent Technologies, Santa Clara, 
CA, USA) was used to enrich the 592 whole-gene targets that 
comprised a 592-gene NGS panel. All variants were detected 
with >99% confidence based on allele frequency and baited 
capture pull-down coverage with an average sequencing 
depth of over 500X and an analytic sensitivity of 5% variant 
frequency.
Total mutation burden
Total mutation burden (TMB) was calculated based on the 
number of nonsynonymous somatic mutations identified by 
NGS while excluding any known single nucleotide polymor-
phism (SNP) in dbSNP (version 137) or in the 1000 Genomes 
Project database (phase 3; http://www.internationalgenome.
org/). TMB is reported as mutations per megabase sequenced. 
The threshold for determining high TMB as greater than or 
equal to 10 mutations/megabase was established.
PD-L1 immunohistochemistry
PD-L1 immunohistochemistry (IHC) analysis was per-
formed on slides of  formalin-fixed paraffin-embedded 
(FFPE) tumor samples using automated staining tech-
niques. The procedures met the standards and requirements 
of  the College of  American Pathologists. The primary anti-
body against PD-L1 was SP142 (Spring Bioscience, Pleas-
anton, CA, USA), except for Non-small cell lung cancer 
(NSCLC) tumors tested after January 2016. For NSCLC 
tumors tested after January 2016, the primary PD-L1 anti-
body clone was 22c3 (Dako, Santa Clara, CA, USA). For 
the calculations in this manuscript, staining for both anti-




Twelve patients were included in this retrospective report. 
Eleven had clear cell histology, but one had translocation- 
type histology. Patient characteristics are summarized in 
Table 1. The median time from RCC diagnosis to adrenal 
metastasis was 68 months (range 0–252 months), and the 
median time from initial metastatic disease to appearance 
of adrenal metastasis was 15 months (range 0–111 months). 
A typical scan showing adrenal metastases is depicted in 
 Figure 1. The sites of metastases are summarized in  Figure 2. 
Four patients had bilateral adrenal metastases.
Three patients presented with adrenal metastases only, and 
were treated with local therapy and achieved complete remis-
sion. Three received high-dose IL-2. One patient received 
high-dose IL-2 for bone metastases and relapsed with a soli-
tary adrenal metastasis 11 years later, which was treated with 
cryotherapy. The same patient developed metastasis in the 
status, calcium, lactate dehydrogenase levels, platelet count, 
and neutrophil count (1). The IMDC criteria prognosti-
cate patients into favorable (0 factors), intermediate (1–2 
risk factors), and poor risk (3 or more factors) categories. 
Despite these standardized criteria, there are multiple other 
factors that determine clinical outcome and require indi-
vidualized management. Sites of  metastases in RCC have 
been noted as an important prognostic factor. For example, 
patients with lungs only metastases were shown to have a 
better outcome than the patients with other sites of  metas-
tases (2). Pancreas metastases in RCC have been reported to 
demonstrate an especially prolonged disease course (3,  4). 
Patients with bone metastases have worse outcomes (5). 
Adrenal metastasis as a special category with unique clin-
ical outcomes has not been reported so far within kidney 
cancer.
Immune checkpoint therapies (ICI) have changed the 
landscape of  kidney cancer therapeutics (6). The potential 
for durable remission is an attractive feature of  ICI-based 
therapy. A favorable toxicity profile than the cytokine 
regimens has enabled wider clinical applications of  ICI 
therapies. We observed multiple cases that had adrenal 
metastases as the only residual sites, or sites of  relapse after 
immune-based regimens. Our clinical observations noted a 
distinct clinical course in RCC patients with adrenal metas-
tases. A unique pattern of  resistance to ICI was also noted 
in RCC cases with adrenal metastases. We compiled a case 
series of  RCC patients with adrenal metastases to evaluate 
the features of  clinical course, presentation, and response 
to ICI therapy. The report also sheds light on the nuances 
of  specific clinical management of  adrenal metastases cases 
within RCC.
Patients and Methods
The protocol was reviewed and exemption was granted by 
the Wayne State University Institutional Review Board. We 
reviewed a case series of patients at Karmanos Cancer Cen-
ter with advanced RCC who presented with adrenal metasta-
ses from RCC, either as a solitary site or as dominant areas 
of relapse/residual disease. Medical records were reviewed to 
collect patient information regarding demographics, sites of 
metastases, IMDC prognostic risk characteristics, therapy, 
response rates, and progression free and overall survival. 
Molecular profiling data were collected if  available.
Tissue testing
Next-generation sequencing
Next-generation sequencing (NGS) was performed on 
genomic DNA isolated from formalin-fixed paraffin-em-
bedded (FFPE) tumor samples using the NextSeq platform 
(Illumina Inc., San Diego, CA, USA). A custom-designed 
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Table 1: Case summaries of advanced renal cancer with adrenal metastases.
Patient characteristic No. (%)
Median age (range) 49.5 years; range 41–80 years
Gender: male/female 12 (100%)/0 (0%)
Race: AA/CA/Hispanic 1 (8.3%)/10 (83.4%)/1 (8.3%)
Unilateral/bilateral 9 (75%)/3 (25%)
Nephrectomy 11 (91.7%)/1 (8.3%)
Histology: clear cell/translocation xp11 11 (91.7%)/1 (8.3%)
Fuhrman Grade: 2/3/unknown 5 (42%)/4 (33%)/3 (25%)
Median time to adrenal mets (range) 68 months (0–252 months)
Systemic therapy: IL-2/ICI/none/VEGF 3 (25%)/5 (41%)/3 (25%)/1 (9%)
Systemic therapy: anti-VEGF therapy 6 (50%)
Local therapy: Surgery/cryotherapy/microwave/none 3 (25%)/6 (50%)/1 (8%)/2 (17%)
IMDC risk: Fav/Int/poor 4 (33.3%)/8 (66.7%)/0 (0%)
AA, African American; CA, Caucasian; IMDC, International Metastatic Disease Consortium; Fav, favorable; Int, intermediate; IL-2, inter-
leukin-2; ICI, immune checkpoint inhibitor; mets, metastases; VEGF, vascular endothelial growth factor.









Figure 1: Computed tomography and positron emission tomography imaging showing adrenal gland metastasis.
other adrenal 18 months later, which was treated with surgi-
cal resection. He was rendered into complete remission after 
surgical resection and continued with no evidence of disease 
1 year later. Of the other two patients receiving IL-2 ther-
apy, one had unresectable large adrenal masses and is now 
demonstrating response to antivascular therapy. The other 
patient progressed on IL-2 but demonstrated a response to 
ipilimumab and nivolumab at all sites except in the adrenal 
gland. The adrenal lesion was treated with cryoablation. Five 
cases received immune checkpoint inhibitor (ICI) and one 
received antivascular therapy. ICI-based regimens were ipili-
mumab + nivolumab in two patients, and axitinib and pem-
brolizumab, a combination of avelumab and an adenosine 
receptor inhibitor and bevacizumab and atezolizumab, each 
in one patient. ICI therapy was followed by ablation of resid-
ual adrenal metastases in three patients. All patients with 
residual adrenal metastases post-immune therapy responded 
to antivascular therapies or to local ablation. With a median 
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Figure 2: Distribution of location of distant metastases in nine patients with multiple sites of metastases.
follow-up of 9.5 years (range: 4 years to 26 years), one 
patient had expired 17 years after diagnosis. Eleven patients 
are alive and follow-up is ongoing. The systemic and local 
therapy management is summarized in Figure 3.
Genomic Results
Next-generation sequencing and PD-L1 testing results are 
available on five cases, which are summarized in Table 2. All 
cases were PD-L1 negative by IHC. None of the cases had 
BAP1 mutations. Pathogenic mutations in PBRM1, SETD2, 
and VHL were noted. Five patients, all with clear cell his-
tology, had genomic testing done, of which three were on 
adrenal metastasis tissue. Three cases had PBRM1 patho-
genic mutations, of which two also had SETD2 pathogenic 
mutations. Four cases demonstrated pathogenic VHL muta-
tions. Tumor mutation burden was low at <5 mutations/
megabase in all cases. None of the patients had BRCA1 or 
BRCA2 mutations or any other DNA repair mutations. One 
case with ATM mutation was deemed a variant of unknown 
significance. Two cases had NGS conducted on both primary 
and metastases (adrenal and mediastinal metastasis). No 
major differences were noted between NGS results from pri-
mary tumor tissue and metastatic biopsies.
Discussion
Immune checkpoint inhibitor-based regimens in RCC have 
improved clinical outcomes and higher response rates than 
those seen previously with single agent tyrosine kinase 
inhibitor (TKI) (6, 7). We report here a specific organ site 
of metastasis, such as the adrenal gland demonstrating resis-
tance to immune therapy. Management with either local 
therapy alone or a combination of systemic therapy with 
TKI such as pazopanib or cabozantinib followed by local 
therapy is required. The presentation of adrenal metastases 
in RCC falls into the following three main categories: (i) De 
novo presentation with adrenal only metastases; (ii) residual/
sanctuary adrenal metastases that are the only sites of dis-
ease resistant to immunotherapy; and (iii) adrenal metastases 
as a component of overall disease progression, in which case 
novel systemic therapies need to be explored.
Local therapy management for adrenal metastases consists 
of surgical resection, minimally invasive cryoablation/micro-
wave ablation, or stereotactic radiation therapy. Systemic ther-
apy with vascular endothelial growth factor tyrosine kinase 
inhibitor (VEGF-TKI) should be considered to achieve 
tumor size reduction and then attempt local therapy to ren-
der complete remission. The recent results of combinations 
of stereotactic body radiation therapy (SBRT) and immune 
checkpoint-based systemic therapy studies have demonstrated 
response rates and overall outcomes no different than those 
with systemic therapy alone (8, 9). However, if  adrenal lesions 
are present as a sanctuary site after immune therapy, then use 
of local therapy is indicated. Successful and safe local therapy 
of adrenal metastases with surgical resection, percutaneous 
cryoablation/microwave ablation, and SBRT, has been estab-
lished (10–13). A series of melanoma cases presenting with 
solitary adrenal metastases that were treated with local ther-
apy has been reported. No systemic therapy was utilized in 
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Table 2: Clinical course and molecular profile of cases.
Case number/
location







Received IL-2 for RCC with bone mets with CR
Relapsed with bilateral adrenal metastases, 11 and 12.5 years after IL-2 











Clear cell RCC post-nephrectomy









Clear cell RCC post-nephrectomy
Relapsed with lung metastases 46 months after and treated with ICI.
Response seen in lung, but adrenal metastases appeared 67 months after 





ATM VUS exon 26
VHL exon 2
Synchronous presentation with kidney mass and metastases to lung and 
bone. Received ICI therapy and had response at other sites but PD with new 








Post-nephrectomy presented with lung metastases. Received IL-2 and 
progressed. Treated with ICI and had a response in lung but adrenal 
metastasis emerged. Treated with local therapy.
NGS, next-generation sequencing; IHC, immunohistochemistry; PD-L1, programmed death ligand-1; Int, intermediate; VUS, variant of 
uncertain significance; IL-2, interleukin-2; ICI, immune checkpoint inhibitor; RCC, reviewed renal cancer.
those cases (14). A recently reported series consisted of two 
melanoma cases, and one uterine carcinosarcoma case, pre-
senting with adrenal residual metastasis after pembrolizumab 
(15). Local therapy was effective in treating adrenal lesions in 
these cases. The prolonged follow-up in our case series shows 
that in RCC these cases are anticipated to have long-term 
remissions, especially as the other metastatic sites demon-
strated durable remission after ICI therapy.
Molecular profiling enables delivery of personalized ther-
apy and is gradually gaining importance in therapeutic deci-
sions in malignancies. In RCC, the clinical application of 
NGS biomarkers has not been established. The lack of BAP1 
mutations in these tumors is consistent with the indolent 
disease course and better prognosis (16). The lack of pro-
grammed death-ligand 1 (PD-L1) expression and low TMB 
suggest resistance to ICI therapy. PBRM1 loss of function 
mutations appear to be predictive of higher likelihood of 
response to ICI therapy (17). VHL mutations were consistent 
with a response to therapies targeting VEGF. The resistance 
to ICI therapies is not explained on the basis of known bio-
markers from contemporary testing. Exploring other mech-
anisms of resistance by evaluating proteomics, epigenomics, 
or metabolomics maybe required (18).
The reasons for adrenal gland lesions presenting as sanc-
tuary sites are not clear. The simplistic explanation appears 
to be that the tumor microenvironment of glucocorticoids 
within adrenal cortex maybe responsible for development 
of immune-resistant metastases (19). The immunosuppres-
sive milieu is likely to prevent tumor infiltration of lympho-
cytes (TIL), hence promoting progression of metastases (20). 
Inflammatory biomarkers and presence of TIL may indicate 
pathways of resistance to immune checkpoint inhibition and 
are worthy of the future investigation. The limitations of our 
study are the small sample size and the retrospective design. 
However, the findings of a consistent clinical course with 
prolonged follow-up, generate the hypothesis of a unique 
subgroup within RCC. The findings need to be validated in a 
larger multicenter trial.
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Conclusion
Adrenal metastases were noted to be a distinct pattern of 
relapse or sanctuary site in advanced RCC. The relapse/ 
residual disease in adrenals was noted despite durable remis-
sion at other sites. Local management was effective and 
systemic therapy with anti-VEGF therapies demonstrated 
response. No association with currently known genetic muta-
tions was noted. The immunosuppressive tumor environ-
ment milieu in adrenal cortex maybe potentially responsible 
for adrenal sites of metastases that are resistant to immune 
therapy. Further investigation should focus on this unique 
pattern of relapse and optimal management.
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